|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||42.86 - 43.28|
|52 Week Range||38.45 - 50.65|
|PE Ratio (TTM)||10.21|
|Forward Dividend & Yield||1.64 (3.80%)|
|1y Target Est||N/A|
Sanofi (SNY) starts two new phase III studies evaluating isatuximab in combination with other cancer medicines for the treatment of multiple myeloma, a rare blood cancer.
In 3Q17, Eli Lilly's (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.
MANILA, Philippines (AP) — The Philippine government will demand a refund of 3.5 billion pesos ($69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunise hundreds of thousands of children that Sanofi has said could worsen the disease in some cases. "We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalisation and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday. The Philippines last week suspended a national immunisation programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia.
A public body close to France's health ministry last year advised against the use of a dengue vaccine in the country's overseas territories that is currently at the centre of a health scare, regulatory documents show. Concerns surrounding the vaccine, sold by French drugmaker Sanofi under the brand Dengvaxia, have prompted the Philippines to halt its sale and suspend a government programme to immunise hundreds of thousands of children.
Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.
French drugmaker Sanofi said on Tuesday the risk of severe dengue occurring in previously uninfected people given its Dengvaxia dengue vaccine was around two in 1,000 and these individuals recovered with treatment. The vaccine is at a centre of a safety row after new data showed it could worsen dengue in some cases, prompting the Philippines to halt its sale and suspend a government programme to immunise hundreds of thousands of children. Answering criticism about delays in reporting problems, Sanofi said it had only been able to conduct a detailed analysis to determine the impact of previous dengue infection this year, after co-developing a new assay with the University of Pittsburgh.
A Zika vaccine Sanofi SA dropped in September under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported on Monday. In February 2016, the World Health Organization declared the Zika outbreak in Brazil and elsewhere an international public health emergency because of the link between the virus and severe birth defects, touching off a scramble for a vaccine. The ZPIV vaccine, made from inactivated Zika virus particles, was developed by U.S. Army researchers, who in July 2016 had agreed to give Sanofi an exclusive license to complete testing and bring the product to market.
The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases. The safety fears involve possible increased risk to people who had not previously been exposed to the dengue virus prior to vaccination with Dengvaxia. Dengvaxia, the first approved Dengue vaccine, had been forecast by Sanofi to eventually bring in nearly $1 billion in annual sales.
Amgen and Regeneron will battle in 2018 after the latter unveils cardiovascular data for its cholesterol drug Praluent.
The Philippines suspended a dengue fever vaccine that was given to thousands of children and launched an investigation, after the drug’s manufacturer said new evidence showed it could worsen symptoms in ...
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...
Sanofi (SASY.PA) on Monday said it was monitoring outcomes of ongoing public programs involving its dengue vaccine, Dengvaxia, following the launch of a probe in the Philippines. The Philippines ordered an investigation into the immunization of more than 730,000 children with the French drugmaker's product after Sanofi said last week the vaccine should not be recommended for individuals who have not been previously infected by the virus. "It is important to note that the vast majority of those vaccinated to date live in high endemic settings and, therefore, will have had a prior dengue infection before vaccination,", Sanofi said in an emailed statement.
The Philippines ordered an investigation on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi (SASY.PA) that it could worsen the disease in some cases. The World Health Organization said it hoped to conduct a full review by year-end of data on the vaccine, commercially known as Dengvaxia. In the meantime, the WHO recommended that it only be used in people who had a prior infection with dengue.
In 3Q17, Regeneron Pharmaceuticals (REGN) generated revenue of $1.5 billion, which reflected ~23% growth year-over-year and ~2% growth quarter-over-quarter.
The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases. Brazil's healthcare regulator Anvisa said it is now recommending that people who have never been infected with dengue not take the vaccine, which was approved for use in Brazil at the end of 2015. The Brazilian government has not suspended the drug entirely, although the Philippine government has.
MANILA, Philippines (AP) — The manufacturer of a dengue fever vaccine that was suspended in the Philippines after a new study showed a greater risk of severe cases in people without previous infection said Monday it is working with authorities to address fears and share the new information.
Pharmaceutical company Sanofi SA said on Friday that it had ended development of an experimental vaccine for Clostridium difficile infection, after an early look at late-stage trial results indicated a low probability for success. About three million Americans are infected annually with the bacterium - also known as C. diff - which spreads mainly through hospitals, nursing homes and doctors' offices. The move marks the second blow in a week to Sanofi's vaccine program after the Paris-based company on Wednesday said use of its new dengue vaccine will be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the mosquito-borne virus.
Stocks look set for a lower open this morning as tax reform ran into some road blocks in the Senate. The market, however, is off its overnight lows. S&P 500 futures have dipped 0.1%, while Dow Jones Industrial ...
Dec.07 -- Jean-Christophe Pointeau, China country chair at Sanofi, discusses the changes in the Chinese health market, his business strategy in China, his partnerships and the automation of the industry. He speaks on "Bloomberg Markets: Asia" from the Fortune Global Forum in Guangzhou.
A public health scandal escalates in the Philippines. Manila is halting the sale of Dengvaxia after a warning that the dengue vaccine might not be safe. Reuters' Eve Johnson reports on who is now finding themselves in the public crosshairs.
The Philippines orders a probe into the immunisation of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi that it could worsen the disease in some cases. Silvia Antonioli reports.